18th Annual Hematologic Malignancies Demystified

18th Annual Hematologic Malignancies Demystified is organized by MedscapeLIVE and will be held from Jan 31 - Feb 07, 2026.

Description:
The 18th Annual Hematologic Malignancies Demystified conference returns in 2026. Access our virtual conference and earn CME/CE credits with education from our expert faculty. Led by conference chair, Hagop Kantarjian, MD, and a panel of specialists in the hematology field, each session will give attendees a critical appraisal of the data from 2025 and put that data into clinical context. Educational sessions will spotlight practice-changing data from meetings such as ASH.

Our interactive conference center makes it easy to participate in the live virtual sessions, panel discussions, and Q&As. We know that connecting with colleagues is crucial; our forums make it easy to network, share ideas, and catch up with colleagues from around the world.

Learning Objectives:
Upon completion of this activity, participants will:

• Have increased knowledge regarding recent clinical trial data in hematologic malignancies and disorders
• Demonstrate greater confidence in their ability to integrate recent data to personalize treatment for patients with hematologic malignancies and disorders 

Day 1: Saturday, January 31, 2026
Learning Objectives:
Upon completion of this activity, participants will be better able to: 

• Summarize recent clinical safety/efficacy data in multiple myeloma
• Summarize recent clinical safety/efficacy data across lymphoma subtypes
• Summarize recent clinical safety/efficacy data related to benign hematology
• Integrate recent data to personalize treatment management for patients with hematologic malignancies

Day 2: Saturday, February 7, 2026
Learning Objectives:
Upon completion of this activity, participants will be better able to: 

• Summarize recent clinical safety/efficacy data in acute leukemias
• Summarize recent clinical safety/efficacy data in chronic leukemias
• Summarize recent clinical safety/efficacy data related to myeloid malignancies
• Integrate recent data to personalize treatment management for patients with hematologic malignancies